Self-reported symptoms among HIV-lnfected patients on highly active antiretroviral therapy in the ATHENA cohort in the netherlands

HIV Clinical Trials

Volumn 12, Issue 3, 2011, Pages 161-170

  De Boer, I ^a   Prins, Jan ^a   Sprangers, Mirjam ^a   Smit, Colette ^b   Nieuwkerk, Pythia ^a,c  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b STICHTING HIV MONITORING   (Netherlands)

^c NONE   (Netherlands)

Author keywords

antiretroviral therapy; HIV 1 infection; quality of life; self report; symptoms

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; BODY FAT DISTRIBUTION; COHORT ANALYSIS; COUGHING; DIARRHEA; DYSURIA; FEMALE; FOLLOW UP; GROWTH CURVE; HEADACHE; HEALTH; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEG PAIN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; NETHERLANDS; PARESTHESIA; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SELF REPORT; SLEEP DISORDER;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; QUALITY OF LIFE;

EID: 79959484207     PISSN: 15284336     EISSN: 19455771     Source Type: Journal    
DOI: 10.1310/hct1203-161     Document Type: Article

References (28)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodefi ciency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338(13):853-860 (Pubitemid 28135961)
2. Willard S, Holzemer WL, Wantland DJ, et al. Does "asymptomatic" mean without symptoms for those living with HIV infection? AIDS Care. 2009;21(3):322-328
3. Mannheimer SB, Wold N, Gardner EM, et al. Mild-tomoderate symptoms during the fi rst year of antiretroviral therapy worsen quality of life in HIV-infected individuals. Clin Infect Dis. 2008;46(6):941-945 (Pubitemid 351417202)
4. Murri R, Ammassari A, Fantoni M, et al. Disease-related factors associated with health-related quality of life in people with nonadvanced HIV disease assessed using an Italian version of the MOS-HIV Health Survey. J Acquir Immune Defi c Syndr Hum Retrovirol. 1997;16(5):350-356
5. Harding R, Lampe FC, Norwood S, et al. Symptoms are highly prevalent among HIV outpatietns and associated with poor adherence and unprotected sexual intercourse. Sex Transm Infect. 2010;86:520-524
6. Ammassari A, Trotta MP, Murri R, et al. Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature. J Acquir Immune Defi c Syndr. 2002;31(Suppl 3):S123-S127 (Pubitemid 35453571)
7. Duran S, Spire B, Raffi F, et al. Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART. HIV Clin Trials. 2001;2(1):38-45 (Pubitemid 32181748)
8. Gonzalez JS, Penedo FJ, Llabre MM, et al. Physical symptoms, beliefs about medications, negative mood, and long-term HIV medication adherence. Ann Behav Med. 2007;34(1):46-55 (Pubitemid 47481224)
9. Lazo M, Gange SJ, Wilson TE, Anastos K, Ostrow DG, Witt MD, et al. Patterns and predictors of changes in adherence to highly active antiretroviral therapy: longitudinal study of men and women. Clin Infect Dis. 2007;45(10): 1377-1385 (Pubitemid 351411918)
10. Protopopescu C, Raffi F, Roux P, et al. Factors associated with non-adherence to long-term highly active antiretroviral therapy: a 10 year follow-up analysis with correction for the bias induced by missing data. J Antimicrob Chemother. 2009;64(3):599-606
11. Lampe FC, Harding R, Smith CJ, Phillips AN, Johnson M, Sherr L. Physical and psychological symptoms and risk of virologic rebound among patients with virologic suppression on antiretroviral therapy. J Acquir Immune Defi c Syndr. 2010;54(5):500-505
12. Cunningham W, Crystal S, Bozzette S, Hays R. The association of health-related quality of life with survival among persons with HIV infections in the United States. J Gen Int Med. 2005;20:21-27 (Pubitemid 40271034)
13. de Boer-van der Kolk IM, Sprangers MA, Prins JM, Smit C, de WF, Nieuwkerk PT. Health-related quality of life and survival among HIV-infected patients receiving highly active antiretroviral therapy: a study of patients in the AIDS Therapy Evaluation in the Netherlands (ATHENA) Cohort. Clin Infect Dis. 2010;50(2):255-263
14. Jacobson D, Wu A, Feinberg J, for the Outcomes Committee of the Adult AIDS Clinical Trials Group. Healthrelated quality of life predicts survival, cytomegalovirus disease, and study retention in clinical trial participants with advanced HIV disease. J Clin Epidemiol. 2003;56: 874-879 (Pubitemid 37162662)
15. Duran S, Spire B, Raffi F, et al. Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART. HIV Clin Trials. 2001;2(1):38-45 (Pubitemid 32181748)
16. Raboud J, Lesosky M, Sterling S, Phillips E, Walmsley S, Bayoumi A. An estimate of the proportion of symptoms reported in self-administered questionnaires that are captured as adverse drug events in an observational database. HIV Clin Trials. 2007;8(5):311-319 (Pubitemid 350099564)
17. Reilly CA, Holzemer WL, Henry SB, Slaughter RE, Portillo CJ. A comparison of patient and nurse ratings of human immunodeficiency virus-related signs and symptoms. Nurs Res. 1997;46(6):318-323 (Pubitemid 127455091)
18. Chubineh S, McGowan J. Nausea and vomiting in HIV: a symptom review. Int J STD AIDS. 2008;19(11): 723-728
19. Johnson MO, Stallworth T, Neilands TB. The drugs or the disease? Causal attributions of symptoms held by HIV-positive adults on HAART. AIDS Behav. 2003;7(2): 109-117 (Pubitemid 36781506)
20. Harding R, Molloy T, Easterbrook P, Frame K, Higginson IJ. Is antiretroviral therapy associated with symptom prevalence and burden? Int J STD AIDS. 2006;17(6): 400-405 (Pubitemid 43765403)
21. Gras L, Sighem Av, Smit C, et al. Monitoring of Human Immunodefi ciency Virus (HIV) Infection in the Netherlands Report 2007. Amsterdam, The Netherlands: HIV Monitoring Foundation; 2008
22. De Boer J, Sprangers MA, Aaronson N, Lange JM, Dam F van. The feasibility, reliability and validity of the EORTC QLQ-C30 in assessing the quality of life of patients with a symptomatic HIV infection or AIDS (CDC IV). Psych Health. 1994;9:65-77
23. de Boer JB, van Dam FS, Sprangers MA, Frissen PH, Lange JM. Longitudinal study on the quality of life of symptomatic HIV-infected patients in a trial of zidovudine versus zidovudine and interferon-alpha. AIDS. 1993;7(7):947-953 (Pubitemid 23239668)
24. Revicki DA, Sorensen S, Wu AW. Reliability and validity of physical and mental health summary scores from the Medical Outcomes Study HIV Health Survey. Med Care. 1998;36(2):126-137 (Pubitemid 128454304)
25. Wu AW, Rubin HR, Mathews WC, et al. A health status questionnaire using 30 items from the Medical Outcomes Study. Preliminary validation in persons with early HIV infection. Med Care. 1991;29(8):786-798
26. Wu AW, Revicki DA, Jacobson D, Malitz FE. Evidence for reliability, validity and usefulness of the Medical Outcomes Study HIV Health Survey (MOS-HIV). Qual Life Res. 1997;6(6):481-493 (Pubitemid 27431704)
27. Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morb Mortal Wkly Rep. 1992; 41 (RR-17):1-19
28. Silverberg MJ, Jacobson LP, French AL, Witt MD, Gange SJ. Age and racial/ethnic differences in the prevalence of reported symptoms in human immunodeficiency virus-infected persons on antiretroviral therapy. J Pain Symptom Manage. 2009;38(2):197-207